title: Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment.
abstract: BACKGROUND
  Treatment of nail psoriasis remains a challenge.
  
  
  OBJECTIVE
  To evaluate the efficacy of a two-compound product of calcipotriol plus betamethasone dipropionate ointment on nail psoriasis in an open-label study.
  
  
  METHODS
  Twenty-five psoriatic patients with nail involvement and mild cutaneous psoriasis were instructed to apply a calcipotriol-betamethasone valerate ointment formulation once daily for 12 weeks on affected nails. Outcome measures were assessed at baseline and at weeks 4, 8 and 12 using the nail psoriasis severity index (NAPSI).
  
  
  RESULTS
  Twenty-two patients having 114 nails involved at baseline with a mean NAPSI of 5.8 +/- 1.7 were followed up for 12 weeks. The mean NAPSI at the end of the treatment period was reduced to 1.6 +/- 0.6 presenting a 72% improvement. Significant improvement was observed for hyperkeratosis and onycholysis (reduction of mean hyperkeratosis NAPSI from 2.2 +/- 0.5 to 0.5 +/- 0.1 and mean onycholysis NAPSI from 2.0 +/- 0.6 to 0.4 +/- 0.2), moderate improvement for oil drops (reduction of mean oil drop NAPSI from 1.2 +/- 0.4 to 0.8 +/- 0.3) and slight improvement for pitting (reduction of mean pitting NAPSI from 0.8 +/- 0.2 to 0.6 +/- 0.2).
  
  
  CONCLUSIONS
  The calcipotriol plus betamethasone dipropionate two-compound ointment, applied once daily for 12 weeks, was shown to improve nail psoriasis.
authors.affiliation: Nail Unit, Department of Dermatology, A. Sygros Hospital, University of Athens Medical School, Athens GR-16121, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Rigopoulos
authors.forename: S
authors.initials: S
authors.lastname: Gregoriou
authors.forename: C R
authors.initials: CR
authors.lastname: Daniel Iii
authors.forename: H
authors.initials: H
authors.lastname: Belyayeva
authors.forename: G
authors.initials: G
authors.lastname: Larios
authors.forename: P
authors.initials: P
authors.lastname: Verra
authors.forename: C
authors.initials: C
authors.lastname: Stamou
authors.forename: G
authors.initials: G
authors.lastname: Kontochristopoulos
authors.forename: G
authors.initials: G
authors.lastname: Avgerinou
authors.forename: A
authors.initials: A
authors.lastname: Katsambas
mesh_terms: D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004338:Drug Combinations; D006801:Humans; D009260:Nail Diseases / Q000188:drug therapy*; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D003879:Dermatologic Agents; D004338:Drug Combinations; D009824:Ointments; C055085:calcipotriene; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D002117:Calcitriol